Related Experiment Videos
Mediastinal paraganglioma: a surgical experience
M F Herrera1, J A van Heerden, F J Puga
1Department of Surgery, Mayo Clinic, Rochester, MN 55905.
The Annals of Thoracic Surgery
|November 1, 1993
Summary
Mediastinal paragangliomas can cause hypertension and may be malignant. Surgical resection improves outcomes, with benign tumors having excellent survival and malignant tumors having a 50% 10-year survival rate.
Area of Science:
- Oncology
- Endocrinology
- Cardiology
Background:
- Mediastinal paragangliomas are rare neuroendocrine tumors.
- These tumors can secrete catecholamines, leading to hypertension.
- Diagnosis and management can be challenging due to their location and potential for malignancy.
Purpose of the Study:
- To review the clinical characteristics, management, and outcomes of patients with mediastinal paraganglioma.
- To evaluate the factors influencing prognosis and survival in this patient cohort.
Main Methods:
- Retrospective review of 14 patients with mediastinal paraganglioma treated at the Mayo Clinic between 1960 and 1991.
- Analysis of clinical presentation, biochemical activity, surgical management, and histopathological findings.
- Assessment of outcomes including blood pressure normalization, tumor recurrence, metastasis, and survival rates.
Main Results:
- Nine of 14 patients presented with hypertension, and 10 had biochemically active tumors.
- Five lesions were invasive, and six tumors were multicentric.
- Seven patients experienced malignant disease progression (metastases or unresectable lesions).
- Total tumor resection normalized blood pressure in 6 of 8 hypertensive patients.
- 10-year survival was 50% for malignant tumors and 100% for benign tumors.
Conclusions:
- Mediastinal paraganglioma management requires a multidisciplinary approach.
- Surgical resection is crucial for symptom control and improved survival.
- Malignant potential necessitates long-term surveillance.
- Tumor ploidy did not correlate with disease behavior.